Naia Pharmaceuticals, Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Naia Pharmaceuticals, Inc.
The NASH Pipeline: Replete With Targets And New Compounds
The numerous different targets of investigational drugs for the treatment of NASH suggest the jury is still out on which mechanism of action is most likely to prove effective against the condition. Ireland’s Afimmune is the latest company wanting to advance an investigational drug for the disorder into late-stage clinical studies.
Start-Up Execs On The Move, May 2015
Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.
Start-Up Quarterly Statistics, Q1 2015
In Q1 2015 start-ups raised $2.74 billion, a new record. Biopharma companies penned 37 alliances; 13 start-ups were acquired across all industries.
Looking For The New Lantus: Next-Gen Diabetes Hopefuls Defy Risks
The diabetes market presents competitive, commercial, and regulatory challenges, but its size and breadth spur emerging biotechs to develop an ever-wider range of treatments and technologies.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Drug Discovery Tools
- ADMET
- Other Names / Subsidiaries
-
- 9 Meters Biopharma, Inc.
- Innovate Biopharmaceuticals, Inc.
- Naia Metabolic
- Naia Rare Diseases, Inc.
- RDD Pharma Ltd
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice